Should You Buy Royalty Pharma Stock Before Nov. 4?

Royalty Pharma (RPRX) has rallied toward its 52-week high heading into third-quarter 2026 earnings on Nov. 4, setting up a print where expectations already carry momentum.

Analysts forecast 8.7% sales growth and flat earnings. That combination leaves little room for an earnings-driven surprise, which is why the original analysis steers investors toward long-term prospects rather than the short-term catalyst.

The bigger swing factor is the pipeline. Positive updates on cancer treatments and other drug candidates could add upside. The risk runs the other way on pelacarsen: negative news on that candidate could weigh on the stock.

Interpretation: with shares near highs and earnings expected to be flat, the stock appears to be pricing in good news. A clean quarter may not be enough to extend the run, while a pipeline disappointment could hit a stock that has already moved.

The supplied evidence does not provide pricing or earnings details for JNJ, RVMD, RVMDW, or NVS, so this piece centers on RPRX.